Article

Tes, a Specific Mena Interacting Partner, Breaks the Rules for EVH1 Binding

Cell Motility Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London, WC2A 3PX, UK.
Molecular Cell (Impact Factor: 14.46). 01/2008; 28(6):1071-82. DOI: 10.1016/j.molcel.2007.10.033
Source: PubMed

ABSTRACT The intracellular targeting of Ena/VASP family members is achieved via the interaction of their EVH1 domain with FPPPP sequence motifs found in a variety of cytoskeletal proteins, including lamellipodin, vinculin, and zyxin. Here we show that the LIM3 domain of Tes, which lacks the FPPPP motif, binds to the EVH1 domain of Mena, but not to those of VASP or Evl. The structure of the LIM3:EVH1 complex reveals that Tes occludes the FPPPP-binding site and competes with FPPPP-containing proteins for EVH1 binding. Structure-based gain-of-function experiments define the molecular basis for the specificity of the Tes-Mena interaction. Consistent with in vitro observations, the LIM3 domain displaces Mena, but not VASP, from the leading edge and focal adhesions. It also regulates cell migration through a Mena-dependent mechanism. Our observations identify Tes as an atypical EVH1 binding partner and a regulator specific to a single Ena/VASP family member.

Download full-text

Full-text

Available from: David Briggs, Jul 17, 2015
0 Followers
 · 
159 Views
  • Source
    • "One molecular explanation for this could be the sustained expression of CDKN1C and TES within the mesodermal progenitors. CDKN1C and TES are known regulators of cell cycle and cell motility, respectively (Pateras et al. 2006; Boeda et al. 2007), and we demonstrated that knockdown of TES in M-iG7 cells reduces their motility in vitro (Supplemental Fig. 4C). In NS-like cells derived from the GiPSCs, expression of CDKN1C and TES were not sustained despite removal of DNA hypermethylation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epigenetic changes are frequently observed in cancer. However, their role in establishing or sustaining the malignant state has been difficult to determine due to the lack of experimental tools that enable resetting of epigenetic abnormalities. To address this, we applied induced pluripotent stem cell (iPSC) reprogramming techniques to invoke widespread epigenetic resetting of glioblastoma (GBM)-derived neural stem (GNS) cells. GBM iPSCs (GiPSCs) were subsequently redifferentiated to the neural lineage to assess the impact of cancer-specific epigenetic abnormalities on tumorigenicity. GiPSCs and their differentiating derivatives display widespread resetting of common GBM-associated changes, such as DNA hypermethylation of promoter regions of the cell motility regulator TES (testis-derived transcript), the tumor suppressor cyclin-dependent kinase inhibitor 1C (CDKN1C; p57KIP2), and many polycomb-repressive complex 2 (PRC2) target genes (e.g., SFRP2). Surprisingly, despite such global epigenetic reconfiguration, GiPSC-derived neural progenitors remained highly malignant upon xenotransplantation. Only when GiPSCs were directed to nonneural cell types did we observe sustained expression of reactivated tumor suppressors and reduced infiltrative behavior. These data suggest that imposing an epigenome associated with an alternative developmental lineage can suppress malignant behavior. However, in the context of the neural lineage, widespread resetting of GBM-associated epigenetic abnormalities is not sufficient to override the cancer genome.
    Genes & development 03/2013; 27(6):654-69. DOI:10.1101/gad.212662.112 · 12.64 Impact Factor
  • Source
    • "The INV exon is inserted just after the EVH1 domain, which is primarily responsible for the subcellular localization of Ena/VASP proteins and interactions with several signaling proteins such as Lamellipodin (Gertler et al., 1996; Urbanelli et al., 2006; Pula and Krause, 2008). It is therefore possible that the INV exon might influence the function of Mena INV by regulating its EVH1-mediated interactions (Niebuhr et al., 1997; Boeda et al., 2007). The 11a exon is inserted within the EVH2 domain between the F-actin binding motif and the coiled-coil tetramerization site. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have shown previously that distinct Mena isoforms are expressed in invasive and migratory tumor cells in vivo and that the invasion isoform (Mena(INV)) potentiates carcinoma cell metastasis in murine models of breast cancer. However, the specific step of metastatic progression affected by this isoform and the effects on metastasis of the Mena11a isoform, expressed in primary tumor cells, are largely unknown. Here, we provide evidence that elevated Mena(INV) increases coordinated streaming motility, and enhances transendothelial migration and intravasation of tumor cells. We demonstrate that promotion of these early stages of metastasis by Mena(INV) is dependent on a macrophage-tumor cell paracrine loop. Our studies also show that increased Mena11a expression correlates with decreased expression of colony-stimulating factor 1 and a dramatically decreased ability to participate in paracrine-mediated invasion and intravasation. Our results illustrate the importance of paracrine-mediated cell streaming and intravasation on tumor cell dissemination, and demonstrate that the relative abundance of Mena(INV) and Mena11a helps to regulate these key stages of metastatic progression in breast cancer cells.
    Journal of Cell Science 07/2011; 124(Pt 13):2120-31. DOI:10.1242/jcs.086231 · 5.33 Impact Factor
  • Source
    • "Weak but specific interactions may be crucial in the rapidly changing environment of a decapping mRNP. It is well understood that a variety of ligands can interact with a single EVH1 domain (Prehoda et al. 1999; Boeda et al. 2007), and three observations suggest that Dcp1 conforms to this paradigm. First, the Dcp1 PRS-binding site interacts with both Edc1 and Edc2, which promotes a similar coactivating response in Dcp2 (Figs. 3, 4, 6). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cap hydrolysis is a critical step in several eukaryotic mRNA decay pathways and is carried out by the evolutionarily conserved decapping complex containing Dcp2 at the catalytic core. In yeast, Dcp1 is an essential activator of decapping and coactivators such as Edc1 and Edc2 are thought to enhance activity, though their mechanism remains elusive. Using kinetic analysis we show that a crucial function of Dcp1 is to couple the binding of coactivators of decapping to activation of Dcp2. Edc1 and Edc2 bind Dcp1 via its EVH1 proline recognition site and stimulate decapping by 1000-fold, affecting both the K(M) for mRNA and rate of the catalytic step. The C-terminus of Edc1 is necessary and sufficient to enhance the catalytic step, while the remainder of the protein likely increases mRNA binding to the decapping complex. Lesions in the Dcp1 EVH1 domain or the Edc1 proline-rich sequence are sufficient to block stimulation. These results identify a new role of Dcp1, which is to link the binding of coactivators to substrate recognition and activation of Dcp2.
    RNA 02/2011; 17(2):278-90. DOI:10.1261/rna.2382011 · 4.62 Impact Factor
Show more